Contents

Search

dacomitinib (Vizimpro)

Indications: - investigational drug for treatment of lung cancer Dosage: Tabs: 15,30, 45 mg Mechanism of action: - inhibitor of the HER family of tyrosine kinases - irreversibly binds to & inhibits human Her-1, Her-2, & Her-4,

General

small inhibitory antineoplastic agent (ib drug)

Database Correlations

PUBCHEM correlations

References

  1. PubChem: 70693519
  2. RxNorm